Literature DB >> 12618511

Integrating the quality of the cytotoxic response and tumor susceptibility into the design of protective vaccines in tumor immunotherapy.

Salem Chouaib1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12618511      PMCID： PMC151911          DOI： 10.1172/JCI18044

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  13 in total

Review 1.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

2.  Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting.

Authors:  Valérie Dutoit; Robert N Taub; Kyriakos P Papadopoulos; Susan Talbot; Mary-Louise Keohan; Michelle Brehm; Sacha Gnjatic; Paul E Harris; Brygida Bisikirska; Philippe Guillaume; Jean-Charles Cerottini; Charles S Hesdorffer; Lloyd J Old; Danila Valmori
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

Review 3.  The host-tumor immune conflict: from immunosuppression to resistance and destruction.

Authors:  S Chouaib; C Asselin-Paturel; F Mami-Chouaib; A Caignard; J Y Blay
Journal:  Immunol Today       Date:  1997-10

Review 4.  Cancer immunoediting: from immunosurveillance to tumor escape.

Authors:  Gavin P Dunn; Allen T Bruce; Hiroaki Ikeda; Lloyd J Old; Robert D Schreiber
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

5.  Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia.

Authors:  J J Molldrem; P P Lee; C Wang; K Felio; H M Kantarjian; R E Champlin; M M Davis
Journal:  Nat Med       Date:  2000-09       Impact factor: 53.440

6.  Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors.

Authors:  J P Medema; J de Jong; L T Peltenburg; E M Verdegaal; A Gorter; S A Bres; K L Franken; M Hahne; J P Albar; C J Melief; R Offringa
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-18       Impact factor: 11.205

7.  Impaired binding of perforin on the surface of tumor cells is a cause of target cell resistance against cytotoxic effector cells.

Authors:  C Lehmann; M Zeis; N Schmitz; L Uharek
Journal:  Blood       Date:  2000-07-15       Impact factor: 22.113

8.  Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells.

Authors:  Jeffrey J Molldrem; Peter P Lee; Shreya Kant; Eric Wieder; Weidong Jiang; Sijie Lu; Changqing Wang; Mark M Davis
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

9.  Cytotoxic T lymphocytes directed against a tumor-specific mutated antigen display similar HLA tetramer binding but distinct functional avidity and tissue distribution.

Authors:  Hamid Echchakir; Guillaume Dorothée; Isabelle Vergnon; Jeanne Menez; Salem Chouaib; Fathia Mami-Chouaib
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-01       Impact factor: 11.205

10.  Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein.

Authors:  J P Medema; J de Jong; T van Hall; C J Melief; R Offringa
Journal:  J Exp Med       Date:  1999-10-04       Impact factor: 14.307
View more
  7 in total

1.  Regulation of gap junctions in melanoma and their impact on Melan-A/MART-1-specific CD8⁺ T lymphocyte emergence.

Authors:  Houssem Benlalam; Thibault Carré; Abdelali Jalil; Zaeem Noman; Bernard Caillou; Philippe Vielh; Andrés Tittarelli; Caroline Robert; Salem Chouaib
Journal:  J Mol Med (Berl)       Date:  2013-06-07       Impact factor: 4.599

Review 2.  Resistance to anticancer immunity in cancer patients: potential strategies to reverse resistance.

Authors:  B Bonavida; S Chouaib
Journal:  Ann Oncol       Date:  2017-03-01       Impact factor: 32.976

Review 3.  Adding fuel to the fire: immunogenic intensification.

Authors:  Geraldine O'Sullivan Coyne; James L Gulley
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

4.  Transcriptional response to hypoxic stress in melanoma and prognostic potential of GBE1 and BNIP3.

Authors:  Stéphanie Buart; Stéphane Terry; Muhammad Z Noman; Emilie Lanoy; Céline Boutros; Paul Fogel; Philippe Dessen; Guillaume Meurice; Yann Gaston-Mathé; Philippe Vielh; Séverine Roy; Emilie Routier; Virginie Marty; Sophie Ferlicot; Luc Legrès; Morad El Bouchtaoui; Nyam Kamsu-Kom; Jane Muret; Eric Deutsch; Alexander Eggermont; Jean-Charles Soria; Caroline Robert; Salem Chouaib
Journal:  Oncotarget       Date:  2017-10-30

5.  OCT4 and SOX2 Specific Cytotoxic T Cells Exhibit Not Only Good Efficiency but Also Synergize PD-1 Inhibitor (Nivolumab) in Treating Breast Cancer Stem-Like Cells and Drug-Resistant Breast Cancer Mice.

Authors:  Wei Peng; Liang Chang; Wenqiang Li; Yanan Liu; Min Zhang
Journal:  Front Oncol       Date:  2022-03-24       Impact factor: 6.244

6.  Diversity and recognition efficiency of T cell responses to cancer.

Authors:  Tor B Stuge; Susan P Holmes; Sahdev Saharan; Andrea Tuettenberg; Mario Roederer; Jeffrey S Weber; Peter P Lee
Journal:  PLoS Med       Date:  2004-11-30       Impact factor: 11.069

7.  Toll-like receptor 9 agonist enhances anti-tumor immunity and inhibits tumor-associated immunosuppressive cells numbers in a mouse cervical cancer model following recombinant lipoprotein therapy.

Authors:  Li-Sheng Chang; Chih-Hsiang Leng; Yi-Chen Yeh; Chiao-Chieh Wu; Hsin-Wei Chen; Hai-Mei Huang; Shih-Jen Liu
Journal:  Mol Cancer       Date:  2014-03-19       Impact factor: 27.401
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.